Colorectal cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

24 of 46+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer (GLYCOANALYTICS)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugal· EU contribution €207,183· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Glycosylation Codes in Cancer at the Molecular Level: An Interdisciplinary Approach for the Dissection of the Recognition Features of CD44 by Galectins and Selectins (GLYCODECD44)

  Asociacion Centro de Investigacion Cooperativa En Biociencias Cic Biogune· Derio Vizcaya, Spain· EU contribution €194,075· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  GUT-commensal Strain for Cancer Assessment and Notification (GUT-SCAN)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Ion channelome of solid tumours: Novel immunotherapy targets for cancer-specific mRNA and drug delivery (ION-CANDEL)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €217,965· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Target mining for the development of therapeutics against pathogen-induced cancers (TagTIC)

  Paris-Lodron-Universitat Salzburg· Salzburg, Austria· EU contribution €4,281,580· until Dec 2031· 9 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 85 running projects, newest first. Listed amounts together: €233.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

  NCT04844073· Takeda· Updated 24 Sept 2026

  “Sponsor decision based on limited anti-cancer activity of TAK-186.”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Updated 19 Feb 2026

  “business objectives have changed”Registry text, quoted unchanged. Source

• Withdrawn

  Sym004 Versus TAS-102 in Patients With mCRC

  NCT03717038· Symphogen A/S· Updated 4 Feb 2019

  “Study was withdrawn due to administrative reasons”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

  NCT07659795· Verastem, Inc.· Source

• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

  NCT06147037· AstraZeneca· Source

• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

  NCT04844073· Takeda· Source

• S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

  NCT05162755· Institut de Recherches Internationales Servier· Source

• ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

  NCT06714357· National Cancer Institute, Naples· Source

• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

  NCT06682793· A2 Biotherapeutics Inc.· Source

• Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· Dutch Colorectal Cancer Group· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 317
• Genome-Wide Association Study 65

• Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.

  Medicine (Baltimore), Sept 2026

• Exploring the relationship between dietary preferences and rectal cancer risk: A two-sample Mendelian randomization study.

  Medicine (Baltimore), Sept 2026

• To unveil the causal relationship between immunophenotypes and colorectal cancer using two-sample bidirectional Mendelian randomization and mediation analyses.

  Medicine (Baltimore), Jul 2026

• Genetic Links Between Cancer and Coronary Atherosclerosis: A Mendelian Randomization Analysis.

  Hum Mutat, Jul 2026

• Causal effects of blood and urinary biomarkers on cancer risk: A Mendelian randomization study.

  J Int Med Res, Jul 2026

• Causal relationships between gut microbiota, C-reactive protein levels and colorectal cancer: A Mendelian randomization study.

  Medicine (Baltimore), Jul 2026

• Mendelian randomization analysis on the dissecting causal relationships between gut microbiota, circulating metabolites, and colorectal cancer: Insights from the latest evidence.

  Medicine (Baltimore), Jul 2026

• Associations of Dietary Intake Traits and Aging Indicators With Colorectal Cancer: A Mendelian Randomization Study.

  Genes Chromosomes Cancer, Jun 2026

• Mendelian randomization analysis of metabolic blood biomarkers and gastrointestinal cancer risk.

  Adv Clin Exp Med, Jun 2026

• Causal links between diabetes, gut microbiota, and colon cancer: insights from Mendelian randomization.

  Endokrynol Pol, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.